[PPT] - Analysis of HIV-1-specific CTL in the Dsseldorf Patient Thomas PowerPoint Presentation

SLIDE 1

Analysis of HIV-1-specific CTL in the „Düsseldorf“ Patient

Thomas Harrer

Infectious Diseases and Immunodeficiency Unit Department of Medicine 3

SLIDE 2

Düsseldorf Patient: HIV-1-specific Immunity?

2

Did the new host develop an HIV-1-specific immunity?
If yes, how strong is the HIV-1-specific CTL response
High frequencies of HIV-1-specific CTL would indicate

active HIV-1 replication and HIV-1 persistence

HIV-1-specific CTL could play an important role in the

eradicaton of the HIV-1 reservoir

SLIDE 3

Analysis of HIV-1-specific CTL: 2015/ 2016

( patient still on tacrolimus)

3

 HLA-I type: A2,A24, B7, C7  ELISPOT with freshly isolated PBMC:

PBMC were isolated by Ficoll and rested overnight in R10
ELISPOT with 12 peptides corresponding to known CTL epitopes

and two proteins

A2: p17-SL9, RT: IV9, VL9, VL9-V, YV9, PR: KI10-M

Nef: PL10, PL10-F.

A24: gp41-EL9, p24-Il8
B7: Nef: FL9, FL9-T, TM9, RL9,
C7: Nef-RY10
20-AA long Gag-Peptides 2 and 5.
Proteins: gp120, p24
positive control: PHA



SLIDE 4

Analysis of HIV-1-specific CTL:

4

 Results:

very weak response to PHA due to immunosuppression
no significant specifc response to peptides
non-significant reaction to Nef7-FL9

No peptide PHA PHA in other patient

SLIDE 5

Analysis of HIV-1-specific CTL: Peptide Stimulation Assay

5

Stimulation with Peptides + IL2 für 1-2 weeks, then ELISPOT

detects low frequency CTL (1: 2-5 Mill.)
detects naive cells and resting memory cells

 PBMC were stimulated with 6 peptides corresponding

to known CTL epitopes in R10 + IL2

 Peptides used for stimulation:

P17-SL9, RT IV9, RT YV9, Nef-TM9, gp41-EL9, Nef-RY10

 Outgrowing cell lines were tested after two weeks for peptide

recognition in a γ-IFN ELISPOT assay

SLIDE 6

Recognition of RT-peptide YV9 by peptide stimulated CTL no peptide RT-YV9 peptide

6

Blood from 10/ 2015 Blood from 2/ 2016 RT-YV9 peptide no peptide Limiting dilution assays revealed a CTL precursor frequency of ~ 1: 2000 cells within the PBMC

SLIDE 7

1 – H2O 2 – CCR5 wt 3 – CCR5∆32 heterozygous 4 – CCR5∆32 homoygous 5 – PBMC patient 6 RTYV9-CTL line 7 –Nef-fl9-line 8 – GenLadder 50bp (Genaxxon) 9 – Low Molecular Weight DNA Ladder ( NEB)

DP: PBMC: d32 ctgcagctctcattttccatacattaaa gatagtcatcttggggctggtcctgcc gctgcttgtcatggtcatctgctactcg ggaatcctaaaaactctgcttcggtgt cgaaatgagaagaagaggcacaggg ctgtgaggcttatcttcaccatcatgat tgtttattttctcttctgggctccctaca acattg DP RT YV9-CTL line: d32 ctgcagctctcattttccatacattaaa gatagtcatcttggggctggtcctgcc gctgcttgtcatggtcatctgctactcg ggaatcctaaaaactctgcttcggtgt cGaaatgagaagaagaggcacagg gctgtgaggcttatcttcaccatcatga ttgtttattttctcttctgggctccctaca acattgtccttctcctgaa

The RTYV9 CTL carry the d32 deletion in CCR5 The RTYV9 CTL are donor derived

SLIDE 8

Peptide stimulation assays with peptide pools 7/ 2016

8

200 400 600 800 1000 1200

Epitope mapping peptide pool 12/ 13 

KELYPLASL KL9: not recognized EPIDKELYPLASLRS 120 not recognized KELYPLASLRSLFGN 121 recognized PLASLRSLFGNDPSS 122 not recognized LYPLASLRSL recognized LYPLASLRSL A24 epitope YPLASLRSL B7 epitope

SLIDE 9

HLA-restriction analysis of Gag07-121-specific CTL

9

97 5 2 163 92 128 50 100 150 200 A2A24,B7,C7 A2 C7 A2,B7,C7 A2,B7 A2,A24

The association with HLA B7 and HLA A24 demonstrates that both the HLAB7- and the HLA-A24-restricted CTL epitopes within GAG07-121 were recognized.

SLIDE 10

The recognized Gag peptide is located in a functional late domain region of p6

10

late domains promote the release of virus particles from the plasma membrane. The primary Alix binding sequence is located near the C-terminus of p6, between residues 36 and 44 ( 36YPLASLRSL44) with p6- Y36, L41, and L44 being particularly critical for Gag– Alix binding .

SLIDE 11

Stem cell donor : Test on 10th of Jan.2018



Elispot with freshly isolated PBMC: 250 000 cell/ well

RT50YV9: A2
Gag07-121, YL9, LL19
Nef7-V2: B7
Nef11T3: C7
PHA: weak response, transport issue?



Stimulation of 5 Mill. PBMC each with peptides corresponding to CTL epitopes recognized by the Düsseldorf patient.

Gag07-121
Gag-LL10: A24
YL9: B7
RTYV9: A2
No significant response

11

SLIDE 12

Düsseldorf-Patient: 14.March 2018



Elispot with freshly isolated PBMC: 200 000 cells/ Well



37 peptides, corresponding to HIV-CTL-epitopes, 5 peptides and proteines corresponding to JCV, EBV, IMP, CMV.

12

Good response to positive controls PHA and ConA: No response to HIV-specific epitopes. Therefore, there is no sign of viral immune stimulation arguing against a significant viral replication. However, this cannot rule out replication below threshold

SLIDE 13

Düsseldorf-Patient: 14.3.18



Stimulation of 5 Million PBMC with peptides:



Testung after 10 days:

13

RT50 YV9 (A2): YQYMDDLV +++ Gag7-121: KELYPLASLRSLFGN + + LL10: LYPLASLRSL + + A24/B27 epitope YL9: YPLASLRSL - B7 epitope

RT50yV9

SLIDE 14

Gag-specific CTL lines contain the Delta32-CCR5-Deletion

14

1 2 3 4 6

1. B-cell wild type
2. Düsseldorf patient B-cell
3. DNA ladder
4. B-cell heterozygous
5. Düsseldorf patient Gag CTL
6. Negative control

5

SLIDE 15

Summary I:

 The donor developed HIV-1-specific CTL against three

functional important CTL epitopes in RT and Gag

 Despite tacrolimus therapy, CTL lines against RT YV9 and

GAG epitopes grew well after peptide stimulation

 These CTL were not detectable in ELISPOT assays with

freshly isolated PBMC presumably to the iatrogenic immunosuppression.

15

SLIDE 16

Summary II: After Stopp of Tacrolimus in 2018:

 No detection of CTL effector cells using freshly isolated PBMC in g-IFN-

ELISPOT assays

 Good outgrowth of CTL after stimulation with peptides and IL2.  This may be due to

Low frequency of effector CTL (<1:100 000)
Presence of memory cells which have not seen virus for a while and thus need

costimulation in addition to the peptide.

 This is indicating that viral replication is absent or low below threshold of

immune activation.

 However, this cannot rule out small amounts of residual virus.

16

SLIDE 17

Summary III:

 CTL against these epitopes were not detected in the donor´s

PBMC.

 This indicates that the new donor developed an immune

response to HIV-1 surviving transplantation procedure despite strong immunosuppression

 HIV-1-specific CTL could help to decrease viral reservoirs:  Graft versus virus response could help in clearance of HIV.

17

SLIDE 18

Acknowledgment

Christiane Mummert Silke Bergmann Björn Jensen Guido Kobbe Rolf Kaiser, Elena Knops, Eva Heger

18

SLIDE 19

19